Luteolin, a bioflavonoid inhibits Azoxymethane-induced colorectal cancer through activation of Nrf2 signaling

Toxicology Mechanisms and Methods

Volumn 24, Issue 1, 2014, Pages 13-20

  Pandurangan, Ashok Kumar ^a   Ananda Sadagopan, Suresh Kumar ^a   Dharmalingam, Prakash ^a   Ganapasam, Sudhandiran ^a  

^a UNIVERSITY OF MADRAS   (India)

Author keywords

Azoxymethane; Colon cancer; GST; Luteolin; Nrf 2

Indexed keywords

AZOXYMETHANE; CYTOCHROME B5; CYTOCHROME P450; GLUTATHIONE TRANSFERASE ALPHA; GLUTATHIONE TRANSFERASE M1; LUTEOLIN; TRANSCRIPTION FACTOR NRF2;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COLON; COLON CARCINOGENESIS; COLORECTAL CANCER; CONTROLLED STUDY; IMMUNOHISTOCHEMISTRY; LIVER; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

ANIMALS; AZOXYMETHANE; COLORECTAL NEOPLASMS; GENE EXPRESSION REGULATION; LUTEOLIN; MALE; MICE; MICE, INBRED BALB C; NF-E2-RELATED FACTOR 2;

EID: 84890331521     PISSN: 15376516     EISSN: 15376524     Source Type: Journal    
DOI: 10.3109/15376516.2013.843111     Document Type: Article

References (52)

1. Alvares AP, Mannering GJ. (1970). Two-substrate kinetics of drug metabolizing enzyme systems of hepatic microsomes. Mol Pharm 6: 206-12.
2. Ashokkumar P, Sudhandiran G. (2008). Protective role of Luteolin on the status of lipid peroxidation and antioxidant defense against Azoxymethane-induced experimental colon carcinogenesis. Biomed Pharmacother 62:590-7.
3. Ashokkumar P, Sudhandiran G. (2011). Luteolin inhibits cell proliferation during Azoxymethane-induced experimental colon carcinogenesis via Wnt/b-catenin pathway. Invest New Drugs 29: 273-84.
4. Berhane K, Widersten M, Engstrom A, et al. (1994). Detoxication of base propenals and other a, b-unsaturated aldehyde products of radical reactions and lipid peroxidation by humane glutathione transferases. Proc Natl Acad Sci USA 91:1480-4.
5. Board PG, Baker RT, Chelvanayagam G, Jermiin LS. (1997). Zeta, a novel class of glutathione transferases in a range of species from plants to humans. J Biochem 328:929-35.
6. Bock KW, Burchell B, Ditton GJ, et al. (1983). UDP- glucuronosyltransferase activities. Guidelines for consistent interim terminology and assay conditions. Biochem Pharmcol 32:953-5.
7. Boyland E, Chasseaud LF. (1969). The role of glutathione and glutathione S-Transferase in mercapturic acid biosynthesis. Adv Enzymol 32: 173-219.
8. Burstein MJ. (1993). Dietary factors related to colorectal neoplasms. Surg Clin N Am 73:13-29.
9. Cerutti PA. (1985). Prooxidant states and tumor promotion. Science 227: 375-81.
10. Chan JY, Kwong M. (2000). Impaired expression of glutathione synthetic enzyme genes in mice with targeted deletion of the Nrf2 basic-leucine zipper protein. Biochim Biophys Acta 1517: 19-26.
11. Choi EM. (2007). Modulatory effects of luteolin on the osteoblastic function and inflammatory mediators in osteoblastic MC3T3-E1 cells. Cell Biol Int 31:870-7.
12. Cummings BS, Parker JC, Lash LH. (2000). Role of cytochrome P450 and glutathione S-Transferase alpha in the metabolism and cytotoxicity of trichloroethylene in rat kidney. Biochem Pharmacol 59:531-43.
13. Dinkova-Kostova AT, Holtzclaw WD, Kensler TW. (2005). The role of keap1 in cellular protective responses. Chem Res Toxicol 18: 1779-91.
14. Ernster L. (1967). DT-diaphorase. In Colowick SP, Kapalan NO, Estabrook RW, Pullman ME, eds. Methods of enzymology (X). Oxidative and phosphorylation. New York and London: Academic Press, 309-17.
15. Furukawa M, Xiong Y. (2005). BTB protein Keap1 targets antioxidant transcription factor Nrf2 for ubiquitination by the Cullin 3-Roc1 ligase. Mol Cell Biol 25:162-71.
16. Guengerich FP. (1995). Influence of nutrients and other dietary materials on cytochrome P-450 enzymes. Am J Clin Nutr 61:651-8.
17. Habig WH, Pabst MJ, Jacoby BW. (1974). Glutathione S transferase. The first enzymatic step in mercapturic acid formation. J Biol Chem 249:1730-7.
18. Hayes JD, Pulford DJ. (1995). The glutathione S-Transferase supergene family regulation of G.S.T.and the contribution of the isoenzymes to cancer chemoprotection and drug resistance. Crit Rev Biochem Mol Biol 30:445-60.
19. Hayes JD, Flanagan JU, Jowsey IR. (2005). Glutathione transferases. Annu Rev Pharmacol Toxicol 45:51-88.
20. Hayes JD, Kerr LA, Cronshaw AD. (1989). Evidence that glutathione S-Transferases B1B1 and B2B2 are the products of separate genes and that their expression in human liver is subject to inter-individual variation. Biochem J 264:437-45.
21. Hayes JD, Strange RC. (1995). Potential contribution of the glutathione S-Transferase supergene family to resistance to oxidative stress. Free Rad Res 22:193-207.
22. Hirayama A, Yoh K, Nagase S, et al. (2003). EPR imaging of reducing activity in Nrf2 transcriptional factor-deficient mice. Free Radic Biol Med 34:1236-42.
23. King C, Tang W, Ngui J, et al. (2001). Characterization of rat and human UDP-glucuronosyltransferases responsible for the in vitro glucuronidation of diclofenac. Toxicol Sci 61:49-53.
24. Kobayashi M, Yamamoto M. (2005). Molecular mechanisms activating the Nrf2-Keap1 pathway of antioxidant gene regulation. Antioxid Redox Signal 7:385-94.
25. Krishnan K, Ruffin 4th MT, Brenner DE. (2000). Chemoprevention for colorectal cancer. Crit Rev Oncol Hematol 33:199-219.
26. Kumar A, Pandurangan AK, Lu F, et al. (2012). Chemopreventive sphingadienes downregulate wnt signaling via a PP2A/Akt/GSK3b pathway in colon cancer. Carcinogenesis 33:1726-35.
27. Lee JS, Surh YJ. (2005). Nrf2 as a novel molecular target for chemoprevention. Cancer Lett 224:171-84.
28. Lowry OH, Rusebrough NJ, Farr AL, Randall RJ. (1951). Protein measurement with folin-phenol reagent. J Biol Chem 193: 265-75.
29. Mannervik B, Danielson U. (1988). Glutathione-Transferases-structure and catalytic activity. CRC Crit Rev Biochem Mol Biol 23: 283-337.
30. Moon YJ, Wang X, Morris ME. (2006). Dietary flavonoids: Effects on xenobiotic and carcinogen metabolism. Toxicol In Vitro 20: 187-210.
31. Morrow CS, Cowan KH. (1990). Glutathione S-Transferases and drug resistance. Cancer Cells 2:15-22.
32. Motohashi H, Katsuoka F, Engel JD, Yamamoto M. (2004). Small Maf proteins serve as transcriptional cofactors for keratinocyte differentiation in the Keap1-Nrf2 regulatory pathway. Proc Natl Acad Sci USA 101:6379-84.
33. Nebert DW, Gelboin HV. (1968). Substrate-inducible microsomal aryl hydroxylase in mammalian cell culture. l. Assembly and properties of induced enzyme. J Biol Chem 243:6242-9.
34. Omura T, Sato R. (1964). The carbon monoxide binding pigment of liver microsomes. J Biol Chem 239:2370-8.
35. Osburn W, Wakabayashi N, Misra V, et al. (2006). Nrf2 regulates an adaptive response protecting against oxidative damage following diquat-mediated formation of superoxide anion. Arch Biochem Biophys 454:7-15.
36. Pandurangan AK. (2013). Potential targets for the prevention of colorectal cancer: A focus on PI3K/Akt/mTOR and Wnt pathways. Asian Pac J Cancer Prev 14:2201-5.
37. Pandurangan AK, Ganapasam S. (2013a). Luteolin induces apoptosis in azoxymethane-induced colon carcinogenesis through involvement of Bcl-2, Bax, and Caspase-3. J Chem Pharm Res 5:143-8.
38. Pandurangan AK, Ganapasam S. (2013b). Luteolin modulates cellular thiols on Azoxymenthane-induced colon carcinogenesis. Asian J Exp Biol Sci 4:245-50.
39. Pandurangan AK, Dharmalingam P, Anandasadagopan SK, Ganapasam S. (2012). Effect of luteolin on the levels of glycoproteins during azoxymethane-induced colon carcinogenesis in mice. Asian Pac J Cancer Prev 13:1569-73.
40. Pandurangan AK, Dharmalingam P, Ananda Sadagopan SK, et al. (2013). Luteolin induces growth arrest in colon cancer cells via wnt/b-catenin signaling mediated through GSK-3b. J Environ Pathol Toxicol Oncol 32:131-9.
41. Patel R, Ingle A, Maru GB. (2008). Polymeric black tea polyphenols inhibit 1, 2-dimethylhydrazine induced carcinogenesis by inhibiting cell proliferation via Wnt/b-catenin pathway. Toxicol Appl Pharmacol 227:136-46.
42. Philips AH, Langdon RG. (1962). Hepatic triphospho-pyridine nucleotide cytochrome C reductase. Isolation, characterization and kinetic studies. J Biol Chem 237:2562-660.
43. Smith G, Stanley LA, Sim E, et al. (1995). Metabolic polymorphisms and cancer susceptibility. Cancer Surv 25:27-65.
44. Sohn OS, Ishizaki H, Yang CS, Fiala ES. (1991). Metabolism of azoxymethane, methylazoxymethanol and N-nitrosodimethylamine by cytochrome P450IIE1. Carcinogenesis 12:127-131.
45. Srinivasan P, Suchalatha S, Babu PVA, et al. (2008). Chemopreventive and therapeutic modulation of green tea polyphenols on drug metabolizing enzymes in 4-Nitroquinoline 1-oxide induced oral cancer. Chem Biol Inter 172:224-34.
46. Tew KD. (1994). Glutathione associated enzymes in anticancer drug resistance. Cancer Res 54:4313-20.
47. Wolf CR, Hayard JP, Lawrie SS, et al. (1987). Cellular heterogeneity and drug resistance in two ovarian adenocarcinoma cell lines derived from a single patient. Int J Cancer 39:695-702.
48. Yang CS, Brady JF, Hong JY. (1992). Dietary effects on cytochromes P450, xenobiotic metabolism, and toxicity. FASEB J 6:737-44.
49. Yoshitani SI, Tanaka T, Kohno H, Takashima S. (2001). Chemoprevention of azoxymethane-induced colon carcinogenesis by dietary capsaicin and roenone. Int J Oncol 19:929-39.
50. Zhang DD. (2006). Mechanistic studies of the Nrf2-keap1 signaling pathway. Drug Metabolism Rev 38:769-89.
51. Zhang ZM, Yang XY, Yuan JH, et al. (2009). Modulation of NRF2 and UGT1A expression by epigallocatechin-3-gallate in colon cancer cells and BALB/c mice. Chin Med J 122:1660-5.
52. Zhu H, Zhang L, Itoh K, et al. (2006). Nrf2 controls bone marrow stromal cell susceptibility to oxidative and electrophilic stress. Free Radic Biol Med 41:132-43.